Protecting the Ocular Surface in Cataract Surgery: The Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution.

artificial tears cataract surgery dry eye hyaluronic acid hydroxypropyl guar ocular surface

Journal

Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512

Informations de publication

Date de publication:
2020
Historique:
received: 25 04 2020
accepted: 09 06 2020
entrez: 4 7 2020
pubmed: 4 7 2020
medline: 4 7 2020
Statut: epublish

Résumé

To evaluate the effects of a hydroxypropyl guar (HPG) and hyaluronic acid (HA) ophthalmic solution in terms of post-cataract surgery dry-eye disease (DED) prevention. In this retrospective study, the data of 419 patients not previously affected by DED, who had undergone unilateral cataract surgery in 17 Italian centers with different perioperative lubricating regimens, were retrospectively reviewed. Patients who had instilled HPG/HA solution 3 times/day in the preoperative week and for two postoperative months were included in group A; group B only instilled HPG/HA for two postoperative months; group C did not instill any perioperative artificial tears. All patients followed the same antibiotic and anti-inflammatory postoperative topical regimen. The scores of SPEED (Standard Patient Evaluation of Eye Dryness) questionnaire, tear break-up time (BUT) and corneal fluorescein staining (CFS, Oxford scale), performed at the preoperative visit and at one, four and eight postoperative weeks, were evaluated. In groups A and B, the SPEED scores were significantly lower than group C in the whole postoperative period. In group A, the SPEED scores were significantly lower than group B 1 and 4 weeks after surgery (p<0.001 and p=0.021). In group C, 25% of patients reported symptom scores corresponding to mild-moderate dry eye 4 and 8 weeks after surgery. The fluorescein tear BUT in groups A and B was significantly higher than group C in the whole postoperative period (p<0.001). In group A, BUT was significantly higher than group B 4 weeks after surgery (p=0.016). More patients showed no corneal fluorescein staining (CFS grade=0) in groups A and B than group C at all the postoperative visits. The hydroxypropyl guar and hyaluronic acid ophthalmic solution was effective at reducing post-cataract surgery ocular discomfort and tear instability, particularly if also administered in the preoperative period.

Identifiants

pubmed: 32616996
doi: 10.2147/OPTH.S259704
pii: 259704
pmc: PMC7326168
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1769-1775

Informations de copyright

© 2020 Favuzza et al.

Déclaration de conflit d'intérêts

Eleonora Favuzza reports personal fees from Alcon Laboratoires and Johnson & Johnson Vision, outside the submitted work. Rita Mencucci reports personal fees from Laboratoires Thea, Alfa Intes, Alcon Laboratoires, Santen, and Johnson & Johnson Vision, outside the submitted work. The authors report no other conflicts of interest in this work.

Références

Clin Ophthalmol. 2017 Aug 07;11:1423-1430
pubmed: 28848324
Clin Ophthalmol. 2017 May 02;11:817-827
pubmed: 28496300
Clin Ophthalmol. 2018 Dec 05;12:2499-2508
pubmed: 30584269
PLoS One. 2013 Nov 12;8(11):e78657
pubmed: 24265705
Clin Ophthalmol. 2011;5:783-90
pubmed: 21750611
Cornea. 2018 Jul;37(7):893-898
pubmed: 29504953
J Cataract Refract Surg. 2018 Sep;44(9):1090-1096
pubmed: 30078540
Curr Opin Ophthalmol. 2010 Jul;21(4):310-6
pubmed: 20467319
Bull World Health Organ. 2004 Nov;82(11):844-51
pubmed: 15640920
J Ocul Pharmacol Ther. 2015 Oct;31(8):491-7
pubmed: 26067908
Korean J Ophthalmol. 2009 Jun;23(2):65-73
pubmed: 19568353
Cornea. 2016 Feb;35(2):175-80
pubmed: 26655485
Eye Vis (Lond). 2017 May 10;4:13
pubmed: 28497070
Cornea. 2013 Sep;32(9):1204-10
pubmed: 23846405
Eye (Lond). 2010 Aug;24(8):1331-7
pubmed: 20300126
Adv Ther. 2020 Apr;37(4):1664-1674
pubmed: 32185729
J Cataract Refract Surg. 2019 May;45(5):669-684
pubmed: 31030780
J Cataract Refract Surg. 2015 Aug;41(8):1699-704
pubmed: 26432128
Br J Ophthalmol. 2004 Jun;88(6):821-5
pubmed: 15148219
Cornea. 1993 Sep;12(5):433-6
pubmed: 8306665
Curr Opin Ophthalmol. 2016 Jan;27(1):24-30
pubmed: 26569526
Ocul Surf. 2017 Jul;15(3):511-538
pubmed: 28736341
Cornea. 2003 Oct;22(7):640-50
pubmed: 14508260

Auteurs

Eleonora Favuzza (E)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Eye Clinic, University of Florence, Florence, Italy.

Michela Cennamo (M)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Eye Clinic, University of Florence, Florence, Italy.

Lidia Vicchio (L)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Eye Clinic, University of Florence, Florence, Italy.

Fabrizio Giansanti (F)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Eye Clinic, University of Florence, Florence, Italy.

Rita Mencucci (R)

Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), Eye Clinic, University of Florence, Florence, Italy.

Classifications MeSH